Post by Paula Doust Alba

Another light few weeks in terms of CNS & Rare Disease news. Eisai & Biogen's Leqembi receive positive MHRA decision in the UK alongside negative NICE guidance on NHS reimbursement for the drug. Avidity Biosciences close an upsized public offering of common stock. BioMarin announce leadership changes as new EVP Chief R&D Officer and EVP CBO are appointed. #neuroscience #raredisease #leqembi #leadership